The higher levels of IL-2 obtained in disease-free patients found to be contributing to a more stable neoadjuvant effect of targeted therapy and chemotherapy by rapidly promoting recruitment and activation of natural killer (NK) and cytotoxic CD8+ T lymphocytes at the tumor site, and enhancing trastuzumab-mediated ADCC (16,18). Here, CD8A is linked to neoplasm.